Overexpression <strong>of</strong> <strong>the</strong> transcriptional repressor activated B cell factor 1 (ABF-1) in HRS cells. ABF-1 inhibits, in combination with <strong>the</strong> inhibitor <strong>of</strong> differentiation 2 (Id2), <strong>the</strong> B cell-specific gene expression program in Hodgkin/Reed-Sternberg cells <strong>of</strong> classical Hodgkin lymphoma. ABF-1 mRNA and protein overexpression in HRS-derived compared to non-Hodgkin cell lines shown in (A). ABF-1 mRNA expression analysis <strong>of</strong> primary HRS cells by in situ hybridization is shown in (B). A B from apoptosis. In addition, we showed that p53-dependent apoptosis can be induced in HRS cells by <strong>the</strong> MDM2-antagonist nutlin-3, and thus <strong>the</strong> activation <strong>of</strong> <strong>the</strong> p53 pathway might represent a novel treatment strategy for cHL. These data provide insights into <strong>the</strong> deregulated apoptosis and survival signaling pathways in HRS cells. Plasticity <strong>of</strong> neoplastic B cells in Hodgkin lymphoma Franziska Jundt, Özlem Acikgöz, Rolf Schwarzer, Ursula Ellinghaus, Nina Mielke in collaboration with Lucio Miele (Chicago, USA) Our group is interested in molecular mechanisms which might contribute to <strong>the</strong> plasticity <strong>of</strong> neoplastic B cells in Hodgkin lymphoma. We are studying <strong>the</strong> role <strong>of</strong> Notch1 which is aberrantly expressed in Hodgkin and Reed- Sternberg (HRS) cells. Notch1 is a receptor which is essential for <strong>the</strong> maintenance <strong>of</strong> <strong>the</strong> stem cell pool and for cell fate decisions in hematopoietic lineages. Subject <strong>of</strong> our investigations is <strong>the</strong> function <strong>of</strong> aberrant Notch1 activity in germinal center-derived HRS cells, which have lost <strong>the</strong> B cell phenotype despite <strong>the</strong>ir mature B cell origin. The development <strong>of</strong> B cells critically depends on a transcription factor network. We showed that Notch1 disrupts <strong>the</strong> B cell-specific transcription factor network by antagonizing B cell-specific transcription factors and by inducing <strong>the</strong> expression <strong>of</strong> B lineage-inappropriate genes. We demonstrated that Notch1 binds directly to <strong>the</strong> B cell commitment factor Pax5 and aberrantly expressed Notch1 suppresses <strong>the</strong> B cell transcription <strong>of</strong> E2A and EBF. Fur<strong>the</strong>rmore, we revealed that Notch1 induces <strong>the</strong> expression <strong>of</strong> activated B cell factor (ABF)-1. 124 Cancer Research
Structure <strong>of</strong> <strong>the</strong> Group Group Leader Pr<strong>of</strong>. Dr. Bernd Dörken Scientists Dr. Stephan Mathas Dr. Martin Janz Dr. Franziska Jundt Dr. Sophie Cayeux Dr. Stephan Kreher Dr. Andreas Lietz Dr. Sabine Friedl Dr. Rolf Schwarzer Dr. Özlem Acikgöz Dr. Thorsten Stühmer* Graduate Students Björn Lamprecht Ursula Ellinghaus Nina Mielke Mario Bunse Branka Cakarun Dirk Rosentreter Sarika Jain* Technical Assistants Simone Lusatis Franziska Hummel Brigitte Wollert-Wulf Ute Nitschke Katharina Kley * part <strong>of</strong> <strong>the</strong> period reported The importance <strong>of</strong> aberrantly expressed ABF-1 is underlined by recent studies from our group, in which we showed that ABF-1 antagonizes <strong>the</strong> B cell-determining factor E2A in HRS cells. Fur<strong>the</strong>rmore, Notch1 led to enhanced expression <strong>of</strong> <strong>the</strong> macrophage-associated gene colony-stimulating factor 1 (c-fms) and T cell-associated transcription factors T-bet and TCF-1. These data suggest that Notch determines <strong>the</strong> unique HRS cell phenotype through aberrant expression <strong>of</strong> B lineage-inappropriate genes. In order to find regulatory mechanisms <strong>of</strong> <strong>the</strong> Notch1 signaling pathway, we analyzed <strong>the</strong> expression <strong>of</strong> Deltex-1, a key modulator and cytoplasmatic inhibitor <strong>of</strong> Notch1. Deltex-1 downregulates Notch1 via beta-arrestin and is known to be expressed in germinal center B cells. We showed that Deltex-1 is not expressed in B-cell derived neoplastic cells in Hodgkin lymphoma. Taken toge<strong>the</strong>r, our data suggest that Notch1 contributes to plasticity <strong>of</strong> B cells in Hodgkin lymphoma and that its aberrant activation is partly caused by absence <strong>of</strong> its inhibitor Deltex-1. Novel <strong>the</strong>rapeutic approach to <strong>the</strong> treatment <strong>of</strong> lymphoma / leukemia by targeting minor histocompatibility antigens Sophie Cayeux (in cooperation with W. Uckert, <strong>MDC</strong>) In <strong>the</strong> treatment <strong>of</strong> leukemia allogeneic bone marrow transplantation is an effective <strong>the</strong>rapeutic option with curative potential. In relapsing disease post-transplantation, it has become evident that donor lymphocyte infusions can potentially induce clinical remissions by generating a graft-versus-leukemia reaction in patients. More recently, minor histocompatibility antigens have been shown to play a clear role in this effect. The ability to isolate T cell receptors that bind specifically to defined minor histocompatibility antigen expressed on tumour cells and subsequently clone <strong>the</strong>m in retroviral vectors has rendered feasible <strong>the</strong>ir transfer to donor or patient T cells. The resulting genetically modified T cells can be used as <strong>the</strong>rapy to eliminate tumour cells. We have developed a single cell PCR method that enables a high throughput approach and facilitates <strong>the</strong> cloning <strong>of</strong> specific mouse T cell receptors from single T cells. In parallel, an in vivo mouse model was established using MHC matched strains differing in <strong>the</strong> minor histocompatibility antigen H13. Following allogeneic bone marrow transplantation, relapsing disease was detected by means <strong>of</strong> a noninvasive in vivo bioluminescence imaging technique and treatment with donor lymphocyte infusions targeting H13 on host tumour cells was performed. The efficacy <strong>of</strong> <strong>the</strong> anti-H13 <strong>the</strong>rapeutic approach and <strong>the</strong> induction <strong>of</strong> a graftversus-tumour reaction were investigated. Selected Publications Lietz, A, Janz, M, Sigvardsson, M, Jundt, F, Dörken, B, Mathas S. (2007). Loss <strong>of</strong> HLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis. Br J Haematol. 137, 342-348. Mathas*, S, Janz*, M, Hummel, F, Hummel, M, Wollert-Wulf, B, Lusatis, S, Anagnostopoulos, I, Lietz, A, Sigvardsson, M, Jundt, F, Jöhrens, K, Bommert, K, Stein, H, Dörken, B. (2006). Intrinsic inhibition <strong>of</strong> E2A by overexpressed ABF-1 and Id2 is involved in reprogramming <strong>of</strong> <strong>the</strong> neoplastic B cells in classical Hodgkin lymphoma. Nature Immunol. 7, 207-215. *contributed equally Janz, M, Hummel, M, Truss, M, Wollert-Wulf, B, Mathas, S, Jöhrens, K, Hagemeier, C, Bommert, K, Stein, H, Dörken, B, Bargou, RC. (2006). Classical Hodgkin lymphoma is characterized by high constitutive expression <strong>of</strong> activating transcription factor 3 (ATF3) which promotes viability <strong>of</strong> Hodgkin/Reed- Sternberg cells. Blood. 107, 2536-2539. Jundt, F, Raetzel, N, Müller, C, Calkhoven, CF, Kley, K, Mathas, S, Lietz, A, Leutz, A, Dörken, B. (2005). A rapamycin derivative (everolimus) controls proliferation through down-regulation <strong>of</strong> truncated CCAAT enhancer binding protein β and NF-κB activity in Hodgkin and anaplastic large cell lymphomas. Blood. 106, 1801-1807. Mathas, S, Jöhrens, K, Joos, S, Lietz, A, Hummel, F, Janz, M, Jundt, F, Anagnostopoulos, I, Bommert, K, Lichter, P, Stein, H, Scheidereit, C, Dörken, B. (2005). Elevated NF-{kappa}B p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large cell, and o<strong>the</strong>r peripheral T cell lymphomas. Blood. 106, 4287-4293. Cancer Research 125
- Page 1 and 2:
Research Report 2008 MDC Berlin-Buc
- Page 3 and 4:
Research Report 2008 (covers the pe
- Page 5 and 6:
Cell Polarity and Epithelial Morpho
- Page 7 and 8:
Molecular Cell Biology and Gene The
- Page 9 and 10:
Foreword Vorwort As this book was b
- Page 11 and 12:
which survey the quality of protein
- Page 13 and 14:
Two major grants from the Helmholtz
- Page 15 and 16:
Cardiovascular and Metabolic Diseas
- Page 17 and 18:
ing on this topic have made importa
- Page 19 and 20:
explain why a certain gene or seque
- Page 21 and 22:
Figure 2. Uptake of lipoprotein (A)
- Page 23 and 24:
Molecular Mechanisms in Embryonic F
- Page 25 and 26:
Cardiovascular Hormones Michael Bad
- Page 27 and 28:
Angiogenesis and Cardiovascular Pat
- Page 29 and 30:
Hypertension, Vascular Disease, Gen
- Page 31 and 32:
Structure of the Group Group Leader
- Page 33 and 34:
Structure of the Group Group Leader
- Page 35 and 36:
eceptors did not change. Thus, syst
- Page 37 and 38:
Mechanisms of Hypertensioninduced T
- Page 39 and 40:
Differentiation and Regeneration of
- Page 41 and 42:
Heart Diseases Coordinator: Ludwig
- Page 43 and 44:
Structure of the Group Group Leader
- Page 45 and 46:
Structure of the Group Group Leader
- Page 47 and 48:
Structure of the Group Group Leader
- Page 49 and 50:
Structure of the Group Group Leader
- Page 51 and 52:
Structure of the Group Group Leader
- Page 53 and 54:
Figure 1. 3D-model of the actomyosi
- Page 55 and 56:
Cell Polarity and Epithelial Morpho
- Page 57 and 58:
Molecular and Cell Biology of the (
- Page 59 and 60:
Structure of the Group Group Leader
- Page 61 and 62:
Structure of the Group Group Leader
- Page 63 and 64:
number of circulating antibodies to
- Page 65 and 66:
Genetics, Genomics, Bioinformatics,
- Page 67 and 68:
Physiology and Pathology of Ion Tra
- Page 69 and 70:
Technical Assistants Alexander Fast
- Page 71 and 72:
Structure of the Group Group Leader
- Page 73 and 74:
Structure of the Group Group Leader
- Page 75 and 76:
Structure of the Group Group Leader
- Page 77 and 78:
Structure of the Group Group Leader
- Page 79 and 80:
Cancer Research Krebsforschung Coor
- Page 81 and 82:
how they infiltrate surrounding tis
- Page 83 and 84:
(Photo: David Ausserhofer/Copyright
- Page 85 and 86:
degradation (ERAD) pathway. In the
- Page 87 and 88: Structural and Functional Genomics
- Page 89 and 90: ated with the deregulation of cell
- Page 91 and 92: A B C Only functional Met keratinoc
- Page 93 and 94: I) Conditional ablation of the Bmp
- Page 95 and 96: Genetics of Tumor Progression and M
- Page 97 and 98: Signaling Mechanisms in Embryonic S
- Page 99 and 100: Surgical Oncology Peter M. Schlag O
- Page 101 and 102: Structure of the Group Group Leader
- Page 103 and 104: Structure bition of differentiation
- Page 105 and 106: Structure of the Group Group Leader
- Page 107 and 108: such as self-renewal and differenti
- Page 109 and 110: Signal Transduction in Tumor Cells
- Page 111 and 112: Structure of the Group Group Leader
- Page 113 and 114: Structure of the Group Group Leader
- Page 115 and 116: Control of DNA Replication Manfred
- Page 117 and 118: Nuclear Signalling and Chromosomal
- Page 119 and 120: Structure of the Group Group Leader
- Page 121 and 122: a. b. Figure 1. The Sleeping Beauty
- Page 123 and 124: Structural and Functional Genomics
- Page 125 and 126: A B Figure 2. Palmitoylation of the
- Page 127 and 128: RNA Chemistry Eckart Matthes Hydrox
- Page 129 and 130: Structure and Membrane Interaction
- Page 131 and 132: Tumor Immunology Coordinator: Marti
- Page 133 and 134: Formation of segregated ectopic fol
- Page 135 and 136: Regulatory Mechanisms of Lymphocyte
- Page 137: Biology and Targeted Therapy of Lym
- Page 141 and 142: Structure of the Group Group Leader
- Page 143 and 144: Structure of the Group Group Leader
- Page 145 and 146: A Figure 1. Function of BH3-only pr
- Page 147 and 148: Molecular Immunotherapy Antonio Pez
- Page 149 and 150: Molecular Immunology and Gene Thera
- Page 151 and 152: Molecular Cell Biology and Gene The
- Page 153 and 154: Structure of the Group Group Leader
- Page 155 and 156: A B C D CD39+ Treg cells and multip
- Page 157 and 158: Experimental Pharmacology Iduna Fic
- Page 159 and 160: Structure of the Group Group Leader
- Page 161 and 162: Function and Dysfunction of the Ner
- Page 163 and 164: (Photo: Dr. Hagen Wende, Research G
- Page 165 and 166: tion of proteins causes human neuro
- Page 167 and 168: - Pathophysiological Mechanisms of
- Page 169 and 170: Structure of the Group Group Leader
- Page 171 and 172: Stucture of the Group Group Leader
- Page 173 and 174: Structure of the Group Group Leader
- Page 175 and 176: What are the physiological features
- Page 177 and 178: Structure of the Group Group Leader
- Page 179 and 180: Visualization of the UniHi interact
- Page 181 and 182: Dagmar Ehrnhöfer* Manuela Jacob* M
- Page 183 and 184: Structure of the Group Group Leader
- Page 185 and 186: Lack of axonal bifurcation within t
- Page 187 and 188: Molecular Physiology of Somatic Sen
- Page 189 and 190:
Mitochondrial Dynamics Christiane A
- Page 191 and 192:
Neuronal Stem Cells Gerd Kempermann
- Page 193 and 194:
Targeting Ion Channel Function Ines
- Page 195 and 196:
RNA Editing and Hyperexcitability D
- Page 197 and 198:
Molecular Neurology Frauke Zipp T h
- Page 199 and 200:
Structure of the Group Group Leader
- Page 201 and 202:
Academics Akademische Aktivitäten
- Page 203 and 204:
Charité-Universitätsmedizin Berli
- Page 205 and 206:
Helmholtz Fellows Helmholtz-Stipend
- Page 207 and 208:
(Photo: Cécile Otten, Research Gro
- Page 209 and 210:
2007 19. January Neujahrsempfang de
- Page 211 and 212:
Speaker Institute Titel of Seminar
- Page 213 and 214:
Speaker Institute Titel of Seminar
- Page 215 and 216:
Speaker Institute Titel of Seminar
- Page 217 and 218:
Overview Überblick
- Page 219 and 220:
erzielen, brauchen wir neue gemeins
- Page 221 and 222:
The Clinical Research Center (CRC)
- Page 223 and 224:
y such scientists in conjunction wi
- Page 225 and 226:
Zudem bietet das ECRC-Modell eine h
- Page 227 and 228:
(Photo: David Ausserhofer/ Copyrigh
- Page 229 and 230:
Business School” addressed challe
- Page 231 and 232:
Prof. Dr. Gary R. Lewin MDC Berlin-
- Page 233 and 234:
Dr. Thomas Müller Prof. Dr. Claus
- Page 235 and 236:
Type of Financing/Art der Finanzier
- Page 237 and 238:
Collaborative Research Centres (SFB
- Page 239 and 240:
Figures for technology transfer/Ken
- Page 241 and 242:
MDC MAX-DELBRÜCK-CENTRUM FÜR MOLE
- Page 243 and 244:
Buschow, Christian . . . . . . . .
- Page 245 and 246:
Herrmann, Ina . . . . . . . . . . .
- Page 247 and 248:
Mensen, Angela . . . . . . . . . .
- Page 249 and 250:
Schwarzer, Rolf . . . . . . . . . .
- Page 251 and 252:
Campus Map Campusplan Robert-Rössl
- Page 253 and 254:
How to find your way to the MDC Der